Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2025 | Promising results of the MorningSun trial: mosunetuzumab in various lymphoma subtypes

Tara Graff • 3 Sep 2025
SOHO 2025
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Non-Hodgkin Lymphoma Antibodies Mosunetuzumab
MorningSun

Tara Graff, DO, Mission Cancer and Blood, Des Moines, IA, briefly discusses the promising results of the MorningSun trial (NCT05207670), which is evaluating the safety and efficacy of mosunetuzumab in various lymphoma indications, including follicular lymphoma (FL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tara Graff

The operational efficiencies of using one versus multiple bispecific antibodies for DLBCL and FL
1:30
The operational efficiencies of using one versus multiple bispecific antibodies for DLBCL and FL
Tara Graff • 13 Jun 2026
Implementing bispecific antibodies into community practice: overcoming misconceptions & fears
2:14
Implementing bispecific antibodies into community practice: overcoming misconceptions & fears
Tara Graff • 13 Jun 2026
The value of POD24 when personalizing treatment selection in follicular lymphoma
2:26
The value of POD24 when personalizing treatment selection in follicular lymphoma
Tara Graff • 13 Jun 2026
Translating academic-center data to community settings to improve the adoption of bispecifics
1:54
Translating academic-center data to community settings to improve the adoption of bispecifics
Tara Graff • 8 Dec 2025

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals